{"url_path":"/sec/cort/8-k/2026-06-17/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1088856/0001193125-26-274258-index.html","accession_number":"0001193125-26-274258","cik":"0001088856","ticker":"CORT","issuer_name":"CORCEPT THERAPEUTICS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1088856/0001193125-26-274258-index.html","primary_entity_key":"0001088856","primary_entity_name":"CORCEPT THERAPEUTICS INC"},"word_count":59,"has_tables":true,"body_markdown":"Item 8.01.\n\nOther Events.\n\nOn June 17, 2026, Corcept Therapeutics Incorporated (the “Company”) issued a press release announcing that the Company has resubmitted its New Drug Application to the U.S. Food and Drug Administration for relacorilant as a treatment for patients with Cushing’s syndrome. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference."}